产品
编 号：F580383
分子式：C24H26N6O5
分子量：478.5
分子式：C24H26N6O5
分子量：478.5
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 919783-22-5
产品详情
生物活性：
AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research.
体内研究：
AZD1656 (0-9 mg/kg; oral gavage; daily; for 8 weeks; C57BL/6 mice) treatment shows lowered blood glucose and glucose excursion and raised insulin. Liver mRNA levels for various ChREBP target genes including carbohydrate response element binding protein beta isoform (ChREBP-β), G6pc, Pklr, Acly, Acac and Gpd2 are increased by AZD1656.Animal Model:C57BL/6 mice
Dosage:0 mg/kg, 2 mg/kg, 4.5 mg/kg, 9 mg/kg
Administration:Oral gavage; daily; for 8 weeks
Result:Administered 2 hours before the oral glucose tolerance test, lowered blood glucose and glucose excursion and raised insulin.
AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research.
体内研究：
AZD1656 (0-9 mg/kg; oral gavage; daily; for 8 weeks; C57BL/6 mice) treatment shows lowered blood glucose and glucose excursion and raised insulin. Liver mRNA levels for various ChREBP target genes including carbohydrate response element binding protein beta isoform (ChREBP-β), G6pc, Pklr, Acly, Acac and Gpd2 are increased by AZD1656.Animal Model:C57BL/6 mice
Dosage:0 mg/kg, 2 mg/kg, 4.5 mg/kg, 9 mg/kg
Administration:Oral gavage; daily; for 8 weeks
Result:Administered 2 hours before the oral glucose tolerance test, lowered blood glucose and glucose excursion and raised insulin.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备